Ascending Single Dose Study of the Safety, Tolerability, PK and PD of ATN-103 Administered SC or IV to Healthy Japanese Male Subjects.

Trial Profile

Ascending Single Dose Study of the Safety, Tolerability, PK and PD of ATN-103 Administered SC or IV to Healthy Japanese Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2013

At a glance

  • Drugs Ozoralizumab (Primary) ; Ozoralizumab (Primary)
  • Indications Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jan 2013 Drug company changed from Wyeth to Ablynx as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top